Serial Number
98547760
Owner
Inograft Biotherapeutics, Inc.Attorney
John Paul OleksiukFiling Date
May 13, 2024
INOGRAFT BIOTHERAPEUTICS Trademark
Serial Number: 98547760
Trademark Classes
Class 1 - Chemicals
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Owner Contact Info
Legal Representation
Correspondence Address
John Paul Oleksiuk Cooley LLP
1299 Pennsylvania Avenue, NW, Suite 700
Washington, DC 20004
United States
Trademark Details
Filing Date
May 13, 2024
Registration Date
Not Registered
Published for Opposition
December 24, 2024
Goods & Services
Research and development services relating to bone marrow, stem cell, and organ transplantation; research and development in the field of stem cell therapies; research and development relating to bone marrow, stem-cell, and organ transplantation; research and development relating to pharmaceutical preparations as CD47 antagonists, integrin-associated proteins, and CD47 glycoproteins; research and development services in the field of antibodies; research and development relating to using monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants
Stem cell-derived drug therapies being biological preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cell-derived therapeutic pharmaceutical preparations for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; stem cells for therapeutic treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases for medical purposes; pharmaceutical preparations as CD47 antagonists, integrin-associated proteins (IAP), and CD47 glycoproteins for the treatment of monogenetic diseases, autoimmune diseases, cancer, and aging-related diseases; monoclonal antibodies for medical purposes; monoclonal antibodies to suppress immune responses that lead to rejection of stem cell and organ transplants for medical purposes
Stem cells for research purposes; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; decoy receptors being biochemicals for in vitro scientific or research use
